GlassScriptPhysician profile
Erin Saltzman
NPI 1720033228
$7,658.15
in general payments reported to CMS, 2019-2025
20 companies · $6,500 in 2025
The $6,500 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $217 · 2022: $168 · 2025: $6,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,500.00 | 2025 | |
| Novo Nordisk INC | $321.59 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $196.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $117.50 | 2019-2020 | |
| Medtronic Minimed, INC. | $78.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.50 | 2019-2020 | |
| Lilly USA, LLC | $69.19 | 2019-2020 | |
| Insulet Corporation | $39.54 | 2019-2020 | |
| Dexcom, INC. | $36.56 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $33.85 | 2022 | |
| Corcept Therapeutics | $31.06 | 2019 | |
| Amgen INC. | $29.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.09 | 2019 | |
| Tandem Diabetes Care, INC. | $25.63 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $13.80 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $13.75 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.74 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.66 | 2020 | |
| Pfizer INC. | $12.50 | 2019 | |
| Ibsa Pharma INC. | $11.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Saltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.